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Renoprotective effects of VPI versus ACEI in normotensive Proteinuria and hypertension are main determinants
nephrotic rats on different sodium intakes. of progressive renal function loss [1], and reduction of
Background. Control of blood pressure (BP) and optimal blood pressure and/or urinary protein loss is the corner-reduction of proteinuria (Uprot) are necessary for long-term reno-
stone of renoprotective intervention [2, 3]. Agents in-protection. Unfortunately, angiotensin-converting enzyme in-
terfering in the renin-angiotensin system (RAS) havehibitors (ACEI) and angiotensin II (Ang II) antagonists are
not effective during sodium repletion. Vasopeptidase inhibitors proven particularly useful: Angiotensin-converting en-
(VPI) cause dual inhibition of ACE and neutral endopeptidase, zyme inhibitors (ACEI) and angiotensin II (Ang II) an-
the latter resulting in decreased atrial natriuretic peptide (ANP) tagonists lower both blood pressure and proteinuria ef-breakdown and thus enhanced natriuresis. Therefore, in con-
fectively [4].trast with ACEI, VPI may be effective during high sodium intake.
The effect on both proteinuria and blood pressure hasMethods. To test this hypothesis, the renoprotective actions
of the new VPI gemopatrilat (GEM) were studied during low to be optimal, since it has been shown that more reno-
(0.05% NaCl) and high (3.0% NaCl) sodium diets in normo- protection is afforded with increasing therapy effects
tensive Wistar rats with established adriamycin nephrosis. The
on these parameters. Unfortunately, ACEI and Ang IIACEI lisinopril (LIS) was used as control. Rats received either
antagonists are ineffective during sodium repletion; di-GEM (0.3 mg/g chow), an equihypotensive dose of LIS (75
mg/L drinking water), or vehicle (VEH) from week 6 (that etary sodium restriction or diuretic treatment is neces-
is, established Uprot) until sacrifice. The effect of therapy was sary in order to obtain full therapeutic efficacy [5, 6].
monitored by measuring systolic BP and Uprot (weekly) and The new class of vasopeptidase inhibitors (VPI) pro-
structural renal damage at the end of study (week 16).
vides dual inhibition of ACE and neutral endopeptidaseResults. During low sodium, GEM effectively reduced Uprot
(NEP) [7]. The latter results in decreased breakdown of(48  4%), but LIS was more effective (80  2%), while
Uprot slightly increased in VEH (23 2%). The focal glomeru- atrial natriuretic peptide (ANP), thus promoting natri-
losclerosis (FGS) score after GEM (38  14) was lower than uresis, diuresis, and vasodilation [8, 9]. Therefore, vaso-
in the VEH group (79  27), although this was not significant. peptidase inhibitors can be considered as ACE inhibitorsLIS (18  6) reduced FGS significantly. Remarkably, on high
with an intrinsic diuretic action, which may not be depen-sodium, GEM was completely ineffective in reducing BP, Uprot
dent on sodium restriction for therapeutic efficacy. Thisand structural renal injury, just like LIS.
Conclusions. The renoprotective actions of VPI depend on assumption is supported by its strong antihypertensive
dietary sodium intake in normotensive nephrotic rats: thera- action in high- as well as low-renin conditions [10]. The
peutic efficacy is fully blunted by a high sodium diet. During concept of vasopeptidase inhibition has been investi-a low sodium diet, gemopatrilat was renoprotective, but less
gated extensively in various cardiovascular diseases andeffective than lisinopril. Whether higher doses of the VPI could
improve its renoprotective efficacy remains to be elucidated. has proven remarkably effective in treating hypertension.
In contrast, experience in renal disease is scarce, and
limited to hypertensive renal disorders [11–13]. In these
models this mode of treatment appears to be renoprotec-
tive. The renoprotective actions of VPI have not been
tested, however, in normotensive models of proteinuria-Key words: adriamycin nephrosis, gemopatrilat, lisinopril, proteinuria,
renoprotection, dietary sodium, vasopeptide inhibition. induced renal damage.
In the present study we therefore investigated whetherReceived for publication December 4, 2001
the VPI gemopatrilat is renoprotective in adriamycin ne-and in revised form May 1, 2002
Accepted for publication August 12, 2002 phrosis, a normotensive rat model of proteinuria-induced
renal damage. Assuming that VPI is effective, irrespec- 2003 by the International Society of Nephrology
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treatment with ACEI (lisinopril), with VPI (gemopatri-
lat) or vehicle until termination in week 16. Thus, there
were 6 groups: group 1, LS, VPI (N  15); group 2, LS,
ACEI (N  15); group 3, LS, vehicle (N  6); group 4,
HS, VPI (N  15); group 5, HS, ACEI (N  15); and
group 6, HS, vehicle (N 6). Group sizes were based on
the expected differences in proteinuria and FGS between
the active treatment groups.
Throughout the experiment groups of rats were housed
in cages with free access to food and drinking water in
a room maintained at 20C and 60% humidity with a 12
hour light-dark cycle. Body weight and intake of food
and water (24-hour stay in metabolic cages) were mea-
sured weekly. Urine was sampled for measurement of
24-hour proteinuria and creatinine. Reference values for
Fig. 1. Study design. At t 6 weeks the rats were stratified according to creatinine clearance and blood pressure were obtainedproteinuria into the following treatment groups: gemopatrilat; lisinopril;
from healthy Wistar rats.vehicle.
Dosing of drugs
Gemopatrilat is a vasopeptidase inhibitor with a higher
tive of dietary sodium content, the main hypothesis was potency to inhibit ACE than NEP. It has previously been
that—in contrast to ACEI—VPI would still exert thera- shown in rats that 24 hours after a single dose of 10 mg/kg,
peutic benefit during high sodium. The second hypothe- inhibition of renal ACE was approximately 50% and inhi-
sis was that VPI would be at least as effective as ACEI bition of renal NEP was approximately 30% [15]. Gemo-
during low sodium. To test this hypothesis, we studied patrilat was mixed with chow at a concentration of 0.3
the effects of gemopatrilat on proteinuria and develop- mg/g (Hope Farms Inc.) resulting in a dose of 14 mg/kg1/
ment of structural renal injury in nephrotic rats on low day1. This concentration was derived from preliminary
and high sodium intake. The effects of an equihypoten- experiments in adriamycin-nephrotic rats in our labora-
sive dose of the ACEI lisinopril were studied as a control, tory where we established that this dose proved equipo-
thus precluding differences in blood pressure control as tent to the used dose of lisinopril as to reduction of blood
a cause of different short-term (proteinuria) and long- pressure. Lisinopril was provided at 75 mg/L in the drinking
term (glomerulosclerosis) therapeutic efficacy. water, corresponding with a mean daily dose of 9 mg/
kg1/day1. Previous experiments in adriamycin nephrotic
rats demonstrated that this dose results in maximal re-METHODS
duction of proteinuria [16].
Study protocol
MeasurementsIn our normotensive model of established adriamycin
nephrosis, proteinuria develops gradually after a single Systolic blood pressure measurements were performed
injection of adriamycin (2.0 mg/kg in the tail vein, weekly after two weeks of daily training prior to induc-
isoflurane-anesthesia) and interventions start six weeks tion of nephrosis. An automated multichannel system
afterwards, that is, at established proteinuria [14]. Effi- was used with tail cuffs and photoelectric sensors to detect
cacy of treatment is monitored by weekly measurement the tail pulse (Apollo 179; IITC Life Science, Woodland
of proteinuria and blood pressure and, at the end of Hills, CA, USA). The rats were placed in a test chamber
study, the degree of glomerular and interstitial injury. in restrainers while temperature was maintained at 27
The experiment was approved by the local Committee to 29C. For each rat, the value was calculated from the
for Animal Experiments. Our study protocol is shown mean of two consecutive measurements.
in Figure 1. Immediately after arrival, male Wistar rats The urinary concentration of protein was determined
(Hsd.Cpd.Wu; Harlan Inc., Zeist, The Netherlands) were with the biuret method (Bioquant; Merck, Darmstadt,
randomized to receive a low sodium (LS, 0.05% NaCl) Germany). Creatinine concentrations were determined by
or a high sodium (HS, 3.0% NaCl) diet (both diets con- a multi-analyzer (SMAC; Technicon, Tarrytown, NY,
tained 20% protein; Hope Farms Inc., Woerden, The USA).
Netherlands). Adriamycin was injected two weeks after All rats were sacrificed in week 16 under isoflurane
arrival (t  0, body weight 346  2.0 g). At six weeks, anesthesia and blood was collected by puncture of the
the rats of each of the sodium groups were stratified into abdominal aorta. Kidneys were perfused with saline and
harvested for histological examination. Tissue was fixedthree groups according to the amount of proteinuria:
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Fig. 2. Systolic blood pressure in the low so-
dium (A ) and high sodium (B ) groups over
time in rats treated with gemopatrilat (),
lisinopril (), or vehicle (). *P  0.05 vs.
vehicle group. Each value represents mean 
SEM of two consecutive weeks.
in 4% paraformaldehyde and embedded in paraffin. Four Data analysis
micrometer sections were cut and stained with periodic Data are expressed as mean  SEM unless stated
acid-Schiff (PAS) for determination of focal glomerulo- otherwise. Baseline values for proteinuria are the mean of
sclerosis (FGS) and interstitial fibrosis (IF). The degree the values in weeks 5 and 6. As the blood pressure (BP)
of FGS was assessed in 50 glomeruli by scoring semi- remained stable during development of proteinuria, the
baseline values for BP are the mean of week 1 throughquantitatively on a scale of 0 to 4 as originally described
week 6. Repetitively determined variables with a para-by Raij, Azar and Keane [17]. FGS was scored positive
metric distribution were tested by two-way ANOVA forwhen mesangial matrix expansion and adhesion of the
repeated measurements with a post-test according toglomerular visceral epithelium to Bowman’s capsule
Bonferroni. In case of non-parametric distribution ofwere present in the same segment. If 25% of the glomeru-
data, analysis of variance (ANOVA) on ranks for re-lus was affected, a score of 1 was adjudged, 50% was
peated measurements was used in combination withscored as 2, 75% as 3 and 100% as 4. The ultimate
Dunn’s method as the post-test. The appropriate vehiclescore is then obtained by multiplying the degree of
treated group was used as control group. Differenceschange by the percentage of glomeruli with the same
between pre- and post-treatment values within a groupdegree of injury and adding these scores, thus rendering
were tested using a paired t test. To test whether the
a theoretical range of 0 to 400. Interstitial fibrosis was incidence of capillary thrombosis was different between
scored semiquantitatively for each individual on a scale the high sodium groups, 2 test was used. Statistical sig-
of 0 to 3, where 0 indicates absence of interstitial fibro- nificance was assumed at the 5% level.
sis and 1, 2 and 3 reflect fibrotic changes in 0 to
25%, 25 to 50% or over 50%, respectively, of the total
RESULTSinterstitial area.
Blood pressure
Premature expiration The systolic blood pressure in healthy rats was 149 
5 mm Hg. Blood pressure remained stable in all groupsAnimals that were found to be severely ill, judged by
after induction of nephrosis until start of treatment, con-general appearance and loss of body weight, were sacri-
firming that this is a non-hypertensive model (Fig. 2).ficed. Whereas no animals were lost in the low sodium
The percentage changes of blood pressure are depictedgroups, a number of high sodium fed rats expired before
in Table 1. In the low sodium groups, both the rats treated
the end of study (Table 2). These rats were excluded with gemopatrilat and those treated with lisinopril showed
from the group data. Most of these rats (10 of 13) expired a clear-cut and similar drop in blood pressure that re-
late in the study, that is, between weeks 12 and 15. To test mained consistently equivalent throughout follow-up.
whether excluding these rats from the analysis influenced The low sodium, vehicle group showed no change in
the interpretation of the over-all results, individual data blood pressure throughout the study. In the high sodium
on proteinuria are shown also for the response at week groups, no significant change in blood pressure was ob-
8, that is, at a time when all animals were still alive; thus, served (Table 1). Thus, neither drug lowered blood pres-
sure during a high sodium diet.no selection by mortality could have occurred.
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Table 1. Group characteristics
Low sodium diet High sodium diet
Vehicle Gemopatrilat Lisinopril Vehicle Gemopatrilat Lisinopril
Body weight g 3969 4087 4085 39916 3894 3856
Baseline proteinuria mg/day 57558 60452 62460 72395 65691 53178
Change proteinuria % 232a 484a,b,c 802a,b 3116a 207a 126a
Baseline blood pressure mm Hg 1543 1524 1464 1474 1464 1513
Change blood pressure % 52 292a,b 312a,b 14 64 55
Data reflect the group characteristics at baseline and their percentage change (mean of week six through sixteen).
aP  0.05 vs. baseline
bP  0.05 vs. vehicle
cP  0.05 vs. Lisinopril
Fig. 3. Proteinuria in the low sodium (A ) and
high sodium (B ) groups over time in rats
treated with gemopatrilat (), lisinopril (),
or vehicle (). *P  0.05 vs. vehicle group,
#P  0.05 vs. gemopatrilat group. Each value
represents mean  SEM of two consecutive
weeks.
Proteinuria and creatinine clearance ence values and the nephrotic groups on low sodium was
statistically significant. No significant differences wereProteinuria developed rapidly during the four weeks
found between the nephrotic groups (Table 2).following injection of adriamycin and subsequently lev-
eled off (Fig. 3). Percentage changes of proteinuria are
Structural renal injuryprovided in Table 1. In the low sodium groups, vehicle
The low sodium group treated with vehicle developedtreated animals showed a modest further rise in protein-
considerable glomerulosclerosis during the 16 weeks ofuria whereas gemopatrilat induced a significant reduc-
nephrosis (Table 2). Gemopatrilat reduced the FGStion of proteinuria (46  6% at week 10). Lisinopril
score considerably, although it just did not reach statisti-induced a powerful antiproteinuric response that stabi-
cal significance. Treatment with lisinopril resulted in alized after four weeks of treatment (84  2% at week
significant reduction in FGS score. Representative glo-10) and was stronger than the reduction obtained by
meruli of each group are shown in Figure 4. Scores forgemopatrilat. These differences were significant, both by
interstitial fibrosis showed similar trends as the FGSrepeated measurements testing, and when tested for each
scores, but failed to reach statistical significance.week separately.
In all three high sodium groups, massive glomerularIn the high sodium groups, neither gemopatrilat nor
damage was observed. A considerable number of ani-lisinopril induced a lowering of proteinuria. Instead, re-
mals in all three groups showed extensive capillarygardless of treatment, proteinuria further increased as
thrombosis. The incidence of capillary thrombosis in thein the vehicle group.
gemopatrilat group and lisinopril group was not statisti-The creatinine clearances in the study groups are shown
cally different from the vehicle group (2 test, P  0.27in Table 2. As expected, the creatinine clearance in these
and P  0.16, respectively). Since these lesions differ bynephrotic groups was lower than reference values obtained
their nature from glomerulosclerosis, no reliable FGSfrom healthy control rats (0.45 mL * min1 * 100 g1;
95% CI 0.36, 0.60), but only the difference between refer- score can be provided for the high sodium groups. No
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Table 2. Parameters at the end of the study
Low sodium diet High sodium diet
Vehicle Gemopatrilat Lisinopril Vehicle Gemopatrilat Lisinopril
N  6 N  15 N  15 N  6 N15 N15
Body weight g 45411 4464 4288 42730 4349 42710
Survival rate 6/6 15/15 15/15 5/6 12/15 9/15
CCr mL * min1 * 100 g1 0.290.04 0.360.02 0.310.02 0.320.10 0.350.04 0.420.04
(N5) (N13) (N14) (N4) (N7) (N8)
Focal glomerulosclerosis 7927 3814 186a ND ND ND
Capillary thrombosis N0 N0 N0 N2 N9 N10
Interstitial fibrosis 1.70.5 1.40.2 1.00.1 1.60.4 2.10.4 2.20.3
Parameters at end of study are shown. Focal glomerulosclerosis (scale 0 to 400) and interstitial fibrosis (scale 0 to 3) are in arbitrary units. ND is not done.
aP  0.05 vs vehicle
bP  0.05 vs Lisinopril
Fig. 4. Renal morphology of adriamycin rats on low sodium diet (A-C ) and high sodium diet (D ). (A) A 2 focal glomerulosclerosis (FGS)
lesion (arrows) from a vehicle-treated rat. (B) An unaffected glomerulus from a lisinopril-treated rat. (C) A 1 lesion (arrows) from a gemopatrilat-
treated rat. (D) Lesions that were found in a subset of adriamycin rats on a high sodium diet, consisting of endocapillary thrombosis and hyalinosis
(arrows).
significant changes in interstitial fibrosis score were found Rats that expired prematurely in the high sodium
groups (Table 2) were excluded from the group analysis.between the high sodium groups. Thus, in high sodium
groups, consistent with the absence of a decline in pro- To explore the possible impact of this selection on the
overall results, the effects of active treatment on protein-teinuria and blood pressure, neither drug resulted in less
histological damage than vehicle-treatment. uria during high sodium were plotted for individual rats
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Fig. 5. Proteinuria during high sodium in individual rats treated with gemopatrilat (A ) or lisinopril (B ). All individual animals that expired
prematurely () featured thrombotic lesions. Of the individuals surviving until the end of the study (circles), some featured capillary thrombosis
(), whereas others did not ().
(Fig. 5). It shows, first, that the individuals that expired The presented data are robust, as they were obtained
during a long follow-up period of ten weeks treatment.before end of study were those with highest proteinuria,
Moreover, the main parameters, that is, proteinuria andthat is, the most severe nephrosis. Second, it shows that
blood pressure, were measured weekly with consistentgemopatrilat and lisinopril were equally ineffective, both
results throughout the study.in the deceased and surviving animals. Finally, this indi-
Adriamycin nephrosis is a normotensive model of pro-vidual analysis also allowed an assessment of the impact
teinuria-induced renal fibrosis and glomerular sclerosisof glomerular capillary thrombosis on the renal therapy
[18]. The importance of proteinuria is underlined by theresponse. In these high sodium groups, the antiprotein-
fact that the efficacy of proteinuria-reduction consistentlyuric response was invariably absent as well as in the ani-
predicts long-term renal outcome during therapy in thismals without capillary thrombosis and in the animals in
model [16], which is in accord with proteinuric renalwhich proteinuria was less severe. An individual analysis
disease in humans [19].of the blood pressure response yielded a similar picture
High levels of proteinuria persisted in all high sodium(data not shown).
groups. Accordingly, no improvement on histological
damage was found in the high sodium groups on active
DISCUSSION treatment. Moreover, a number of animals expired pre-
To our knowledge, this is the first study providing maturely in the last study weeks. Individual analysis of
information on the renoprotective actions of vasopepti- the antiproteinuric responses showed that gemopatrilat
dase inhibition in a normotensive rat model with ne- and lisinopril were both invariably ineffective during high
phrotic range proteinuria. sodium, irrespective whether proteinuria was high or not.
Most remarkably, during a high sodium diet, the VPI Thus far, to our knowledge our study in adriamycin
gemopatrilat was completely ineffective in lowering both nephrosis is the first to document annihilation of the
blood pressure and proteinuria as well as in preventing response to VPI by a high sodium diet. No data are
histological renal damage. This is exactly like the actions available on sodium-dependency of the VPI effects in
models of renal failure. However, our results are at vari-previously found with ACE inhibition. In contrast, dur-
ing a low sodium diet, gemopatrilat rendered a clear-cut ance with studies reporting efficacy of VPI in sodium-
loaded, low-renin models of hypertension [10]. On theand consistent fall in proteinuria and blood pressure.
This demonstrates that gemopatrilat has renoprotective other hand, the present findings are in line with the
results from early ANP infusion-studies in adriamycin-potential in this model, although the difference in FGS
did not reach statistical significance compared to vehicle. induced [20] and aminonucleoside-induced nephrotic
rats [21]. Those studies revealed that there is resistanceThus, in this model, the actions of gemopatrilat depend
on dietary sodium intake in a similar fashion as those of against the acute natriuretic and diuretic actions of this
peptide in the nephrotic syndrome. Thus, ANP resistancean ACEI.
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could explain the present findings. If so, no actions other [11] and benazepril [12]. The VPI S21402, but not the
ACEI captopril, reduced albuminuria significantly inthan inhibition of ACE could be expected of gemopatri-
lat in the present study. It should be recollected, however, SHR [31].
Thus, these data—all obtained in hypertensive mod-that resistance to the acute actions of ANP also was ob-
served in dogs with heart failure [22], that is, another els—seem at variance with our findings. Differences in the
pathophysiology of renal damage in those models anddisorder characterized by sodium-retention, whereas long-
term treatment with VPI is effective in heart failure [23, 24]. ours may be relevant in the discrepancies. In the adria-
mycin model, proteinuria is typically in the nephroticLisinopril was used as a positive control as to the sodium
dependency of the therapy response. Both drugs were range, and the development of renal structural damage is
proteinuria-driven, resulting from the tubulointerstitialcompletely ineffective during high sodium intake. As an-
ticipated, during the low sodium intake, blood pressure toxicity of leaked proteins, without a contribution of
systemic or glomerular hypertension. In the above mod-control by both drugs was equally effective. Neverthe-
less, gemopatrilat was less effective in reducing protein- els, systemic and/or glomerular hypertension are the im-
portant driving forces, proteinuria being much less prom-uria than lisinopril. What could be the mechanism behind
this? inent, and hardly ever in the nephrotic range. Thus,
nephrosis-associated ANP-resistance might be absent inAtrial natriuretic peptide has been shown to cause pre-
glomerular vasodilation and post-glomerular vasocon- those models or—when afferent vasodilation is already
maximal such as in 5/6 nephrectomy—NEP inhibitionstriction in experimental conditions [25, 26]. Consistent
with this observation, studies in diabetic [27, 28] and may not be able to exert further (unfavorable) vasodila-
tion of the afferent arteriole. More or less in accord withnon-diabetic patients [29] have shown that ANP infusion
causes a rise in albuminuria, and acute administration our findings, omapatrilat was less effective than captopril
in preventing glomerular damage in Dahl salt-sensitiveof a NEP inhibitor in renal patients increased albumin-
uria [8]. In the present study, an ANP-induced increase rats [32], in spite of a similar antihypertensive effect and
in spite of marked improvement of endothelial functionof intraglomerular pressure partially could have offset
the antiproteinuric effects of the VPI, and consequently in the renal vasculature. Whereas this is still unexplained,
those data together with our results indicate that it isthe effects on glomerulosclerosis, but intraglomerular
pressure measurements would be needed to support this not warranted to extrapolate data on the renoprotective
potency of VPI in one experimental model to another.assumption.
It also should be recollected that NEP not only cata- Finally, dosing and type of VPI and ACEI could have
contributed to the observed discrepancies. We chose alyzes the degradation of ANP, but also of several other
vasoconstrictive and vasodilative peptides. For example, dose of lisinopril known to induce optimal antihyperten-
sive and antiproteinuric efficacy. In the discussed studies,in vivo inhibition of NEP resulted in endothelin-1 medi-
ated vasoconstriction in human forearm vessels [30]. Ef- the use of different ACEIs and/or dosing below the opti-
mal dose for proteinuria might partially explain the fa-fects on other peptides, therefore, may have resulted in
unforeseen effects in our study. vorable results for the VPI. The relative efficacy of oma-
patrilat and the newer compound gemopatrilat also shouldWe used an equihypotensive dose of the ACEI to
discern possible renoprotective effects of the VPI gemo- be considered. However, in vivo rat studies have indi-
cated that the potency to inhibit ACE and NEP are similarpatrilat independent of its effect on blood pressure. This
is relevant as both blood pressure and proteinuria are for omapatrilat and gemopatrilat [15, 33]. Nevertheless,
we suggest that, in order to find the optimal renoprotec-independent treatment targets in renal disease. Some pre-
vious studies in renal models have not used equipotent tive dose, additional studies with omapatrilat and gemo-
patrilat that specifically aim for the dose-response fordoses of VPI and ACEI, which hampers a comparison
with our data (abstract; Wenzel UO, J Am Soc Nephrol proteinuria need to be performed [34].
Since VPI intervene at several levels in two physiologi-11:343A, 2000) [13, 31]. These studies showed a better
antihypertensive and renoprotective effect of a VPI over cal systems, their actions are rather multiple than dual.
Therefore, the clinical outcome of so-called dual block-an ACEI in two-kidney 1-clipped (2K1C) rats, 5/6 ne-
phrectomized rats and diabetic spontaneously hyperten- ade of ACE and NEP is intricate and depends on patient
factors such as type and severity of disease in combina-sive rats (SHR), respectively. However, the superiority
of the VPI in these studies could be blood pressure de- tion with environmental factors such as dietary sodium
intake.pendent, and it cannot be excluded that a higher dose
of the ACEI also would have improved renal outcome. We demonstrate that the renoprotective actions of
vasopeptidase inhibition in normotensive nephrotic ratsOther studies reported on the renal effects of equi-
potent antihypertensive doses of a VPI and an ACEI. depend on dietary sodium intake: therapeutic efficacy is
fully blunted by a high sodium diet. During a low sodiumIn the 5/6 nephrectomy model, omapatrilat resulted in
better prevention of structural renal injury than enalapril diet, the VPI gemopatrilat provided renoprotection that
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15. Hubner RA, Kubota E, Casley DJ, et al: In-vitro and in-vivohave no benefit over ACEI alone in the treatment of
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enzyme with the vasopeptidase inhibitor gemopatrilat. J Hypertens
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